Drug Profile
Research programme: cystic fibrosis therapy - Takeda/Cystic Fibrosis Foundation Therapeutics
Alternative Names: SHP 636Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Shire
- Developer Cystic Fibrosis Foundation Therapeutics; Takeda
- Class Gene therapies; RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Inhalation, Aerosol)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 01 Feb 2016 Preclinical trials in Cystic fibrosis in USA (Inhalation) before February 2016